| Formulary Chapter 4: Central nervous system - Full Chapter
|
| Chapter Links... |
 MHRA Drug Safety Alert (Feb 2015): Drugs and driving: blood concentration limits set for certain drugs |
 NENC Palliative and End of Life Care Symptom Control Guidelines |
| NICE NG62: Cerebral palsy in under 25s: assessment and management |
| TEWV - Medicines Optimisation – Interactive Guide |
| TEWV Guidelines |
| TEWV Safe Transfer of Prescribing Guidance |
| Details... |
| 04.02.01 |
Antipsychotic Drugs |
|
|
 |
For more information on prescribing antipsychotics in primary care see the North of Tyne, Gateshead and North Cumbria APC Information leaflet prepared by CNTW or the TEWV Medicines Optimisation Interactive Guide (as appropriate):
|
|
|
|
|
|
|
|
|
|
|
|
| 04.02.01 |
First Generation Antipsychotic Drugs |
|
|
| 04.02.01 |
Second Generation Antipsychotic Drugs |
|
|
Risperidone
|
Formulary
|
- Note: risperidone orodispersible tablets should only be used in situations where the plain tablets are unsuitable.
|
MHRA Drug Safety Update (Nov 2013): Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery
|
Amisulpride
|
Formulary
|
|
|
|
Aripiprazole
|
Alternatives
|
- Approved for schizophrenia in people aged 15 to 17 years in line with NICE.
- Approved for moderate to severe manic episodes in young people aged 13 and older with bipolar I disorder NICE.
- Aripriprazole 10mg & 15mg orodispersible tablets are approved for doses over 5mg for those patients who have difficulty swallowing.
- Aripiprazole 1mg in 1ml oral solution is only for doses of 5mg or less, or when titrating patients on doses of increments of less than 5mg, in patients who have difficulty swallowing tablets.
- To be used in accordance with NICE criteria.
- Note: Aripiprazole 7.5mg/ml IM Injection is approved for use in rapid tranquilisation in patients with acute psychosis.
 NTW use only.
|
MHRA Drug Safety Update (December 2023): Aripiprazole (Abilify and generic brands): risk of pathological gambling
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
NICE TA292: Bipolar disorder (children) - aripiprazole
|
Clozapine
|
Alternatives
|
- First choice in patients with treatment-resistant schizophrenia.
|
MHRA Drug Safety Alert (Oct 2017): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
MHRA Drug Safety Update (Aug 2020): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity
North East and North Cumbria ICB - Clozapine supporting guidance for primary care
|
Lurasidone (Latuda®)
|
Alternatives
|
- 18.5mg, 37mg and 74mg tablets
- Approved for the treatment of schizophrenia in adults and adolescents aged 13 years and over
|
NTAG - Lurasidone Treatment Appraisal: Decision Summary
|
Olanzapine
|
Alternatives
|
- Olanzapine orodispersible tablets should only be used in situations where the plain tablets are unsuitable.
- Olanzapine orodispersible tablets and injection are also approved for 2nd/3rd- line use in the management of delirium in critical care patients
 unlicensed indication.
- 10 mg injection
- for rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.
- for delirium at end of life
- 210mg, 300mg & 405mg powder and solvent for suspension for long-acting injection (as olanzapine embonate monohydrate)
- approved for the treatment of schizophrenia in adults within secure psychiatric services
|
|
|
Quetiapine
|
Alternatives
|
- 25mg, 100mg, 150mg 200mg & 300mg tablets
- 50mg, 200mg, 300mg & 400mg prolonged release tablets
- Prolonged release tablets are approved for use in patients who require an outside carer to administer their medicines, and for short term use when rapid dose titration is considered important e.g. where its use might avoid the need to admit the patient to hospital.
- Quetiapine 20mg/ml Oral Suspension (Rosemont) - CNTW only
|
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment.
In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances.
For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing. |
|
Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement.
The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber.
If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care. |
|
Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role https://www.rcgp.org.uk/gpwer), but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. Provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by GPs. |
|
Drugs where prescribing by GPs is appropriate. Can be initiated and prescribed in all care settings, and if appropriate, discontinued without recourse to secondary care. |
|
NOT APPROVED: Drugs that have been considered by NTAG or the NENC ICB Medicines Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria. |
|
UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review. |
|
NOT REVIEWED: Drugs that haven not been reviewed yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in the North East and North Cumbria until such time that a decision is taken on their formulary status. |
|
|
|
